<DOC>
	<DOCNO>NCT00247247</DOCNO>
	<brief_summary>Multi-centre , randomise , parallel-group study , rater-blinded . Total duration study per subject 12 week plus one- two-week screening period . There 6 pre-planned visit per subject : screening visit follow 5 visit . Approximately 300 patient altogether 25 active German study centre 3 active Lithuanian study centre randomise .</brief_summary>
	<brief_title>Comtess® Versus Cabaseril® Add-on Levodopa Treatment Parkinsonian Patients Suffering From Wearing- Off .</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>patient suffer idiopathic Parkinson 's Disease ( PD ) wearingoff phenomenon OFFtime per day &gt; = 60 min first ONperiod morning 35 daily dosage standard levodopa/DDC inhibitor stable antiparkinsonian treatment 3 week prior randomisation symptomatic parkinsonism concomitant treatment nonselective MAO inhibitor selective MAOA inhibitor treat MAOB inhibitor already concomitant treatment one following catecholstructured drug : rimiterol , isoprenaline , adrenaline , noradrenaline , dopamine , dobutamine apomorphine concomitant treatment alphamethyldopa , reserpine , typical atypical neuroleptic , neuroleptic antiemetic ( metoclopramide ) drug antidopaminergic action treatment COMTinhibitors 4 week prior randomisation treatment dopamine agonists 4 week prior randomisation know hypersensitivity ergot derivative entacapone dementia ( MMSE &lt; = 24 ) depression ( Beck Scale &gt; = 17 )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>